Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

11 Nov 2016

Abstract excerpt

We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27833094
DOI: 10.1038/leu.2016.314

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLPMID 27833094Read ↗

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read ↗

Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia modelSemantic proximity Read ↗

Leukemic stem cells and therapy resistance in acute myeloid leukemiaSemantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.Semantic proximity Read ↗

Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockageSemantic proximity Read ↗

Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia PatientsSemantic proximity Read ↗

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patientsSemantic proximity Read ↗

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemiaSemantic proximity Read ↗

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studySemantic proximity Read ↗

Dexamethasone in hyperleukocytic acute myeloid leukemia.Semantic proximity Read ↗

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCTSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.